Antibody-induced  	Antibody-induced  	 JJ	O
failure  	failure  	 NN	O
of  	of  	 IN	O
botulinum  	botulinum  	 JJ	B-NP
toxin  	toxin  	 NN	I-NP
a  	a  	 DT	O
therapy  	therapy  	 NN	O
in  	in  	 IN	O
cosmetic  	cosmetic  	 JJ	B-NP
indications  	indications  	 NNS	I-NP
Botulinum  	Botulinum  	 JJ	I-NP
toxin  	toxin  	 NN	I-NP
( 	( 	 -LRB-	O
BT 	BT 	 NNP	B-NP
)  	)  	 -RRB-	O
is  	is  	 VBZ	O
a  	a  	 DT	O
safe  	safe  	 JJ	O
and  	and  	 CC	O
effective  	effective  	 JJ	O
treatment  	treatment  	 NN	O
for  	for  	 IN	O
cosmetic  	cosmetic  	 JJ	B-NP
indications 	indications 	 NNS	I-NP
.  	.  	 .	O
Formation  	Formation  	 NN	O
of  	of  	 IN	O
BT  	BT  	 NNP	B-NP
antibodies  	antibodies  	 NNS	I-NP
can  	can  	 MD	O
occur  	occur  	 VB	O
but  	but  	 CC	O
has  	has  	 VBZ	O
previously  	previously  	 RB	O
been  	been  	 VBN	O
reported  	reported  	 VBN	O
in  	in  	 IN	O
cosmetic  	cosmetic  	 JJ	B-NP
indications  	indications  	 NNS	I-NP
in  	in  	 IN	O
two  	two  	 CD	O
cases  	cases  	 NNS	O
only 	only 	 RB	O
.  	.  	 .	O
To  	To  	 TO	O
report  	report  	 VB	O
another  	another  	 DT	O
four  	four  	 CD	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
this  	this  	 DT	O
phenomenon 	phenomenon 	 NN	O
.  	.  	 .	O
Two  	Two  	 CD	O
patients  	patients  	 NNS	O
received  	received  	 VBD	O
abobotulinumtoxinA 	abobotulinumtoxinA 	 JJ	O
;  	;  	 :	O
one  	one  	 CD	O
received  	received  	 VBD	O
the  	the  	 DT	O
current  	current  	 JJ	O
formulation  	formulation  	 NN	B-NP
of  	of  	 IN	O
onabotulinumtoxinA  	onabotulinumtoxinA  	 JJ	O
and  	and  	 CC	O
one  	one  	 CD	O
both  	both  	 DT	O
abobotulinumtoxinA  	abobotulinumtoxinA  	 JJ	O
and  	and  	 CC	O
onabotulinumtoxinA 	onabotulinumtoxinA 	 JJ	O
.  	.  	 .	O
Complete  	Complete  	 JJ	B-NP
secondary  	secondary  	 JJ	I-NP
therapy  	therapy  	 NN	I-NP
failure  	failure  	 NN	I-NP
( 	( 	 -LRB-	O
CSTF 	CSTF 	 NNP	B-NP
)  	)  	 -RRB-	O
occurred  	occurred  	 VBD	O
after  	after  	 IN	O
3- 	3- 	 NNP	O
,  	,  	 ,	O
5- 	5- 	 NNP	O
,  	,  	 ,	O
10- 	10- 	 NNP	O
,  	,  	 ,	O
and  	and  	 CC	O
13-injection  	13-injection  	 CD	O
series 	series 	 NN	O
;  	;  	 :	O
cumulative  	cumulative  	 JJ	B-NP
treatment  	treatment  	 NN	I-NP
times  	times  	 NNS	I-NP
of  	of  	 IN	O
18 	18 	 CD	O
,  	,  	 ,	O
16 	16 	 CD	O
,  	,  	 ,	O
25 	25 	 CD	O
,  	,  	 ,	O
and  	and  	 CC	O
65  	65  	 CD	O
months 	months 	 NNS	O
;  	;  	 :	O
and  	and  	 CC	O
cumulative  	cumulative  	 JJ	B-NP
doses  	doses  	 NNS	I-NP
of  	of  	 IN	O
240  	240  	 CD	O
MU  	MU  	 NNP	B-NP
onabotulinumtoxinA 	onabotulinumtoxinA 	 NNP	I-NP
,  	,  	 ,	O
245  	245  	 CD	O
MU  	MU  	 NNP	B-NP
abobotulinumtoxinA 	abobotulinumtoxinA 	 NNP	I-NP
,  	,  	 ,	O
1,180  	1,180  	 NNP	O
MU  	MU  	 NNP	B-NP
abobotulinumtoxinA 	abobotulinumtoxinA 	 NNP	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
120  	120  	 CD	O
MU  	MU  	 NNP	B-NP
onabotulinumtoxinA 	onabotulinumtoxinA 	 NNP	I-NP
/ 	/ 	 CD	O
270  	270  	 CD	O
MU  	MU  	 NNP	B-NP
abobotulinumtoxinA 	abobotulinumtoxinA 	 NNP	I-NP
,  	,  	 ,	O
respectively 	respectively 	 RB	O
.  	.  	 .	O
Average  	Average  	 JJ	B-NP
interinjection  	interinjection  	 JJ	I-NP
intervals  	intervals  	 NNS	I-NP
were  	were  	 VBD	O
87 	87 	 CD	O
,  	,  	 ,	O
273 	273 	 CD	O
,  	,  	 ,	O
150 	150 	 CD	O
,  	,  	 ,	O
and  	and  	 CC	O
119  	119  	 CD	O
days 	days 	 NNS	O
,  	,  	 ,	O
and  	and  	 CC	O
average  	average  	 JJ	O
single  	single  	 JJ	O
doses  	doses  	 NNS	O
were  	were  	 VBD	O
80  	80  	 CD	O
MU  	MU  	 NNP	B-NP
onabotulinumtoxinA 	onabotulinumtoxinA 	 NNP	I-NP
,  	,  	 ,	O
68  	68  	 CD	O
MU  	MU  	 NNP	B-NP
abobotulinumtoxinA 	abobotulinumtoxinA 	 NNP	I-NP
,  	,  	 ,	O
82  	82  	 CD	O
MU  	MU  	 NNP	B-NP
abobotulinumtoxinA 	abobotulinumtoxinA 	 NNP	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
30  	30  	 CD	O
MU  	MU  	 NNP	B-NP
abobotulinumtoxinA 	abobotulinumtoxinA 	 NNP	I-NP
/ 	/ 	 CD	O
30  	30  	 CD	O
MU  	MU  	 NNP	B-NP
onabotulinumtoxinA 	onabotulinumtoxinA 	 NNP	I-NP
.  	.  	 .	O
Risk  	Risk  	 NN	B-NP
factors  	factors  	 NNS	I-NP
for  	for  	 IN	I-NP
CSTF  	CSTF  	 NNP	I-NP
included  	included  	 VBD	I-NP
booster  	booster  	 JJ	I-NP
injections  	injections  	 NNS	I-NP
( 	( 	 -LRB-	O
2  	2  	 CD	O
patients 	patients 	 NNS	O
)  	)  	 -RRB-	O
and  	and  	 CC	O
increased  	increased  	 VBD	O
immune  	immune  	 JJ	O
system  	system  	 NN	B-NP
reagibility  	reagibility  	 NNS	I-NP
( 	( 	 -LRB-	O
1  	1  	 CD	O
patient 	patient 	 NN	O
) 	) 	 -RRB-	O
.  	.  	 .	O
BT  	BT  	 NNP	B-NP
antibody  	antibody  	 NN	I-NP
titers  	titers  	 NNS	I-NP
were  	were  	 VBD	O
2.7 	2.7 	 CD	O
,  	,  	 ,	O
7.0 	7.0 	 CD	O
,  	,  	 ,	O
and  	and  	 CC	O
more  	more  	 JJR	O
than  	than  	 IN	O
10.0  	10.0  	 NNP	O
mU 	mU 	 NNP	B-NP
/ 	/ 	 NNP	I-NP
mL  	mL  	 NNP	I-NP
on  	on  	 IN	O
the  	the  	 DT	O
mouse  	mouse  	 NN	B-NP
diaphragm  	diaphragm  	 NN	I-NP
assay 	assay 	 NN	I-NP
.  	.  	 .	O
CSTF  	CSTF  	 NNP	B-NP
can  	can  	 MD	O
occur  	occur  	 VB	O
after  	after  	 IN	O
cosmetic  	cosmetic  	 JJ	B-NP
BT  	BT  	 NNP	I-NP
injections  	injections  	 NNS	I-NP
in  	in  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
high  	high  	 JJ	O
immune  	immune  	 JJ	O
system  	system  	 NN	B-NP
reagibility  	reagibility  	 NNS	I-NP
and  	and  	 CC	O
in  	in  	 IN	O
patients  	patients  	 NNS	O
receiving  	receiving  	 VBG	B-NP
booster  	booster  	 JJ	I-NP
injections 	injections 	 NNS	I-NP
,  	,  	 ,	O
but  	but  	 CC	O
also  	also  	 RB	O
in  	in  	 IN	O
unremarkable  	unremarkable  	 JJ	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
typical  	typical  	 JJ	O
treatment  	treatment  	 NN	B-NP
parameters 	parameters 	 NNS	I-NP
.  	.  	 .	O
Its  	Its  	 PRP$	O
incidence  	incidence  	 NN	O
is  	is  	 VBZ	O
unknown 	unknown 	 JJ	O
.  	.  	 .	O
Recommended  	Recommended  	 JJ	B-NP
treatment  	treatment  	 NN	I-NP
parameters  	parameters  	 NNS	I-NP
may  	may  	 MD	O
reduce  	reduce  	 VB	O
the  	the  	 DT	O
risk  	risk  	 NN	O
of  	of  	 IN	O
CSTF 	CSTF 	 NNP	B-NP
,  	,  	 ,	O
but  	but  	 CC	O
may  	may  	 MD	O
not  	not  	 RB	O
eliminate  	eliminate  	 VB	O
it 	it 	 PRP	O
.  	.  	 .	O
